

## **Healthcare Innovation Cycle – HealthTech Deliverables Matrix (EU)**

Solution Name: _	 Date:	

	Milestone Name	Overall Description	Clinical	Market/Business	Regulatory/ Approvals	Technology
1)	Need	Insights into unmet clinical needs and available solutions	☐ Unmet needs defined ☐ Disease state characterized	☐ Needs screening & selection ☐ Existing solutions characterized	NA	NA
2)	Idea	Potential solutions to unmet need developed and evaluated	☐ Clinical workflow description ☐ Updated need description ☐ Feedback from >5 clinicians	☐ Competitive landscape ☐ Envisioned Value Proposition	☐ Medical device intended use ☐ Equivalent devices identified	☐ Paper Prototype ☐ Hypothesis & experimental design ☐ Idea screening & selection
3)	Proof of Concept (PoC)	Key component concepts validated in models and value proposition articulated	☐ Feedback from clinicians in >5 settings ☐ Updated need description and workflow	<ul> <li>□ Competing solutions characterization</li> <li>□ Preliminary Value Proposition</li> <li>□ Path to Payment plan</li> <li>□ Stakeholder Map</li> </ul>	☐ Preliminary classification ☐ Preliminary intended use ☐ Preliminary regulatory pathway	<ul><li>☐ PoC prototypes</li><li>☐ Demonstration results</li><li>☐ Institutional IP disclosure</li></ul>
4)	Proof of Feasibility (PoF)	Feasibility of whole solution demonstrated in models and in feedback from stakeholders	☐ Feedback from clinicians in >20 settings ☐ Updated need & workflow descriptions	☐ Feedback from >5 economic buyers ☐ Impact Plan (draft business plan) ☐ Advisory Board	☐ Draft Essential Requirements Checklist ☐ Draft Instructions for use ☐ Institutional approval	"Works Like" &     "Looks Like"     prototypes  Freedom to operate     review  Provisional IP filing



## **Healthcare Innovation Cycle – HealthTech Deliverables Matrix (EU)**

Milestone Name	Overall Description	Clinical	Market/Business	Regulatory/ Approvals	Technology
5) Proof of Value (PoV)	The potential of the solution to work and create value for all stakeholders is demonstrated (Initial commercial investment)	☐ Feedback from	☐ Investor ready business plan ☐ Feedback from >20 economic buyers ☐ Key management team identified ☐ Initial seed investment	☐ Application form to national competent authority ☐ Data requirements ☐ Clinical Investigation approval(s)	<ul> <li>□ "Works Like/Looks Like" prototypes</li> <li>□ BOM, manufacturing plan, and costing</li> <li>□ Full IP application</li> <li>□ Killer technical experiment</li> </ul>
6) Initial Clinical Trials (ICT)	Regulated production of prototypes and collection of clinical and economic data	Conduct Phase 0 and/or 1 clinical trial(s) Peer reviewed publication(s)	☐ Economic data ☐ Feedback from >50 economic buyers ☐ 1st Institutional Investment	☐ Data requirements confirmation ☐ Pre-submission	☐ Manufacture GMP- compliant pilot lots.
7) Validation of Solution (VoS)	The solution is shown to be effective and its value to all stakeholders is validated	☐ Clinical efficacy trials ☐ Peer reviewed publication(s)	☐ Purchasing intent from >10 buyers ☐ 2nd round of institutional investment	Complete Technical File Technical File submission to Notified Body (CE Mark)	GMP Process Planning
8) Approval & Launch (A&L)	Institutional and regulatory approval received, and sales launched	☐ Training materials & support established ☐ Peer reviewed publication(s)	☐ Initial sales	Registration and Listing (CE mark)  CMS Coverage & CPT Code Determination	☐ Finalized GMP process

© CIMIT April 2018 Page 2 of 3



## **Healthcare Innovation Cycle – HealthTech Deliverables Matrix (EU)**

Milestone Name	Overall Description	Clinical	Market/Business	Regulatory/ Approvals	Technology
9) Clinical Use (Use)	The solution is used successfully in day-day clinical practice	☐ Included in local practice guidelines☐ Peer reviewed publication(s)	☐ Profitable sales	☐ Monitoring and Inspections	☐ Patents issued ☐ Improvement plan
10) Standard of Care (SoC)	The solution is recognized as the Standard of Care.	Recommended practice by medical specialty	Dominant market share	NA	NA

© CIMIT April 2018 Page 3 of 3